Supernus Pharmaceuticals' high P/E ratio is sustained by exp...
Supernus Pharmaceuticals' high P/E ratio is sustained by expectations of robust future growth, surpassing market average. Investors' belief in insignificant earnings deterioration risk bolsters the share price.
![](https://pubimg-10000538.picsh.myqcloud.com/202205090000031596276539dbb.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment